Effect of immunosuppressive drugs in immune-mediated inflammatory disease during the coronavirus pandemic.
Federica GiulianiGiulio GualdiPaolo AmerioPublished in: Dermatologic therapy (2020)
The safety of immunosuppressive treatment in patients with Immune-Mediated Inflammatory Diseases (IMIDs) during the Coronavirus pandemic is questioned and it is utmost important for public health. We searched studies trough MEDLINE/EMBASE database, including patient with IMID, undergoing immunosuppressive treatment with a positive diagnosis for SARS-CoV 2. We included 11 studies for the descriptive analysis and 10 studies for the pooled analysis, with a total population of 57 and 53 IMID-affected SARS-CoV-positive patients respectively. Overall no death was reported; 16 patients were hospitalized (30.2%) and only two cases were admitted to Intensive Care Unit (ICU) (3.8%). We found a significant association between the risk of hospitalization and older age (P .03), obesity (P .02), and presence of multi-comorbidity (P .03). No significant association was found between the risk of hospitalization and the use of biological or conventional DMARDs (respectively P .32 and .26), neither when they are used combined (P .85). We found consistent results in the sub-analysis of Psoriasis: 10 patients were hospitalized (31.3%) and only one case was admitted to Intensive Care Unit (ICU) (3.1%) Particular attention should be placed for patients with older age, obesity and multi-comorbidity that are at higher risk of hospitalization.
Keyphrases
- sars cov
- intensive care unit
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- type diabetes
- peritoneal dialysis
- prognostic factors
- oxidative stress
- emergency department
- coronavirus disease
- insulin resistance
- respiratory syndrome coronavirus
- adipose tissue
- working memory
- case report
- electronic health record
- atopic dermatitis
- community dwelling